Voyager Therapeutics (VYGR) Climbed To A 5-Month High On Study Results

Voyager Therapeutics (VYGR) announced positive results from its Phase 1b trial of VY-AADC01 Wednesday morning, in patients with advanced Parkinson's disease. The company expects to begin its Phase 2-3 program later this year.

from RTT - Before the Bell http://ift.tt/2wKZsnG
via IFTTT